GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » Shares Outstanding (EOP)

Intellia Therapeutics (Intellia Therapeutics) Shares Outstanding (EOP) : 93.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Intellia Therapeutics's shares outstanding for the quarter that ended in Dec. 2023 was 93.00 Mil.

Intellia Therapeutics's quarterly shares outstanding increased from Sep. 2023 (89.10 Mil) to Dec. 2023 (93.00 Mil). It means Intellia Therapeutics issued new shares from Sep. 2023 to Dec. 2023 .

Intellia Therapeutics's annual shares outstanding increased from Dec. 2022 (87.10 Mil) to Dec. 2023 (93.00 Mil). It means Intellia Therapeutics issued new shares from Dec. 2022 to Dec. 2023 .


Intellia Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Intellia Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Shares Outstanding (EOP) Chart

Intellia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.20 66.23 74.49 87.10 93.00

Intellia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.10 88.10 88.35 89.10 93.00

Competitive Comparison of Intellia Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Intellia Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Shares Outstanding (EOP) falls into.



Intellia Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Intellia Therapeutics  (NAS:NTLA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Intellia Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Intellia Therapeutics (Intellia Therapeutics) Business Description

Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Executives
Laura Sepp-lorenzino officer: EVP, Chief Scientific Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta officer: EVP, General Counsel C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks officer: EVP, Chief Business Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark officer: EVP, Chief Technical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl officer: EVP, Chief Medical Officer C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard officer: See Remarks C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard director, officer: President and CEO C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty director C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera officer: EVP, General Counsel C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier officer: EVP, Chief Operating Officer C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139

Intellia Therapeutics (Intellia Therapeutics) Headlines

From GuruFocus

Intellia Therapeutics Names Bill Chase to its Board of Directors

By sperokesalga sperokesalga 04-17-2023